Baseline characteristics of patients with systemic sclerosis (SSc) and matched comparators without SSc.
| SSc, n = 76 | Non-SSc, n = 155 | P | |
|---|---|---|---|
| Age at original index date, yrs, mean (SD) | 56.4 (15.8) | 56.1 (15.5) | 0.92 |
| Sex, female | 69 (91) | 141 (91) | 0.96 |
| Race/ethnicity, White | 67 (88) | 146 (95) | 0.070 |
| Length of follow-up, yrs, median (IQR)a | 10.3 (4.0–17.1) | 12.7 (6.4–19.7) | – |
| Smoking status at original index date | 0.44 | ||
| Never | 40 (53) | 83 (55) | |
| Former | 24 (32) | 38 (25) | |
| Current | 11 (15) | 30 (20) | |
| BMI at original index date, kg/m2, mean (SD) | 26.5 (6.0) | 30.9 (19.4) | 0.004 |
| Fulfilled 2013 ACR/EULAR classification criteria | 69 (91) | – | – |
| Skin involvement | – | – | |
| Limited cutaneous | 64 (84) | ||
| Diffuse cutaneous | 10 (13) | ||
| Sine scleroderma | 2 (3) | ||
| Clinical features | – | – | |
| Telangiectasias | 37 (49) | ||
| Calcinosis | 18/74 (24) | ||
| ILD | 7 (9) | ||
| PAH | 6 (8) | ||
| Renal crisis | 6/72 (8) | ||
| GI dysmotility | 37/74 (50) | ||
| Inflammatory arthritis | 35/73 (48) | ||
| Raynaud phenomenon | 71 (93) | ||
| Digital ulcers | 15/31 (48) | ||
| Positive ANA | 69/74 (93) | – | – |
| Scl-70+ | 7/38 (18) | – | – |
| Anticentromere+ | 29/38 (76) | – | – |
| RNAPIII+ | 2/38 (5) | – | – |
Values are expressed as n (%) or n/N (%) unless otherwise indicated.
↵aLength of follow-up from baseline to last follow-up. ACR: American College of Rheumatology; ANA: antinuclear antibodies; EULAR: European League Against Rheumatism; GI: gastrointestinal; ILD: interstitial lung disease; PAH: pulmonary arterial hypertension; RNAPIII: RNA polymerase III.